广泛期小细胞肺癌胸部放疗时机是否重要?
该回顾性研究纳入232例一线诱导化疗后无进展的广泛期小细胞肺癌(ES-SCLC)患者,比较胸部放疗(TRT)与不放疗、以及早期TRT(≤3周期化疗后)与晚期TRT(>3周期)的生存差异。经倾向性评分匹配后,TRT组的总生存、无进展生存和局部区域无复发生存均显著优于非TRT组,但早期与晚期TRT之间无显著差异。
要点
- 一线化疗后无进展的ES-SCLC患者,加用胸部放疗可显著改善生存。
- 早期胸部放疗(≤3周期诱导化疗后)与晚期胸部放疗生存无显著差异。
- 研究为回顾性分析,经倾向性评分匹配减少选择偏倚。
核心结论
- 对于一线化疗后无进展的ES-SCLC患者,加用胸部放疗可显著延长总生存、无进展生存和局部区域无复发生存。
- 早期胸部放疗相比晚期胸部放疗未显示显著生存获益。
研究设计与样本
- 回顾性分析纳入232例一线诱导化疗后无进展的ES-SCLC患者。
- TRT组分为早期TRT(≤3周期诱导化疗后,n=65)和晚期TRT(>3周期,n=122)。
- 采用倾向性评分匹配(PSM)以减少选择偏倚。
主要发现
- 总体中位生存时间、无进展生存和局部区域无复发生存分别为13.2、8.7和14.6个月。
- PSM后TRT组与非TRT组各45例,TRT组的总生存、无进展生存和局部区域无复发生存均显著更长(P < 0.001)。
- PSM后早期TRT组与晚期TRT组各56例,两组生存参数相似(P > 0.05)。
临床怎么用
- 对一线化疗后无进展的ES-SCLC患者,可考虑加用胸部放疗以改善生存。
- 胸部放疗时机(早期或晚期)对生存无显著影响,临床决策可综合考虑。
局限性
- 研究为单中心回顾性分析,可能存在选择偏倚。
- 样本量有限,早期与晚期TRT的比较需进一步前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study evaluated the prognosis of patients with extensive-stage small-cell lung cancer (ES-SCLC) that may be associated with timing of thoracic radiotherapy (TRT). METHODS: ES-SCLC patients (n = 232) without progression were retrospectively analyzed after first-line induction chemotherapy. Patients in the TRT group were stratified as early-TRT (ERT; ≤3 cycles of induction chemotherapy received prior to TRT, n = 65) or late-TRT (LRT; >3 cycles, n = 122). To avoid selection bias, we conducted Propensity Score Matching (PSM) for patients. Overall survival (OS), progression-free survival (PFS), and locoregional recurrence-free survival (LRRFS) were assessed and compared. RESULTS: Overall, the median survival time, PFS, and LRRFS were 13.2, 8.7, and 14.6 months, respectively. After matching by PSM, there were 45 patients total in the TRT/non-TRT groups, and 56 patients total in the ERT/LRT groups. OS, PFS, and LRRFS were significantly longer in the TRT group than the non-TRT group (P < 0.001, all). However, between the ERT and LRT groups these survival parameters were similar (P > 0.05, all). CONCLUSION: For ES-SCLC patients without progression, the addition of TRT after first-line chemotherapy benefited survival greatly. Early TRT showed no significant benefit over late TRT.
引用
- Luo J, Xu L, Zhao L, et al. Timing of thoracic radiotherapy in the treatment of extensive-stage small-cell lung cancer: important or not? Radiat Oncol. 2017. PMID: 28245874. doi:10.1186/s13014-017-0779-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。